DEVELOPMENTAL CHEMOTHERAPY

描述：（申请人的描述）化疗仍然是治疗癌症的一种方法。 癌症治疗的主要手段。在过去的30年里，这笔赠款 允许纪念医院快速测试并将新疗法应用于患者 各种癌症。本项目的总体目标是开展第一阶段的工作， I Memorial开发的新单药和联合治疗研究 用于疾病特异性II期和III期试验的医院。 新研究的最高优先级将给予想法和化合物 在纪念斯隆凯特琳癌症中心开发， 待进行的临床试验将包括两种分子 反应和药代动力学标志物（如适用）。所有的试验 项目为第一阶段研究。本项目中进行的临床试验 将分为三个具体目标。具体目标1是发展 包括格尔德霉素类似物、10 -炔丙基-10 脱氮氨基蝶呤、三氧化二砷、PS 341和脱氧坡噻酮B。具体 目的二是一个靶向治疗方案，利用吡草胺，并针对 在这个假定的分化剂的发展。最后在 具体目标3相关的科学描述，以支持这些试验。每个 这些临床研究将与药代动力学和分子 实验室相关研究。通过这项工作，我们希望确定新的， 为人类恶性肿瘤的成功管理提供更积极的治疗。

DESCRIPTION: (Applicant's Description) Chemotherapy remains one of the principal means of cancer treatment. Over the past 3 decades, this grant has allowed Memorial Hospital to rapidly test and apply new treatments to a variety of cancers. The overall goal of this project will be to conduct Phase I studies of new single agents and combination therapies developed at Memorial Hospital for application in disease specific Phase II and Phase III trials. Highest priority for new studies will be given to ideas and compounds developed within the Memorial Sloan Kettering Cancer Center for which we hold the IND. The clinical trials to be performed will include both molecular markers of response and pharmacokinetics when appropriate. All trials in this project are Phase I studies. The clinical trials performed in this project will be grouped into 3 specific aims. Specific aim 1 is the development of novel agents including geldanamycin analogs, 10 - propargyl-10 deazaaminopterin, arsenic trioxide, PS341, and desoxyepothilone B. Specific Aim Two is a target based therapy program utilizing Pyroxamide and is directed at the development of this putative differentiation agent. Finally, in Specific aim 3 correlative science is described to support these trials. Each of these clinical studies will be linked to pharmacokinetic and molecular laboratory correlative studies. Through this work, we expect to identify new, more active treatments for the successful management of human malignancies.